Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 25, Issue 10, 2006, Pages 920-929

  Abzug, Mark J ^a,k   Pelton, Stephen I ^b   Song, Lin Ye ^c   Fenton, Terence ^c   Levin, Myron J ^a   Nachman, Sharon A ^d   Borkowsky, William ^e   Rosenblatt, Howard M ^f   Marcinak, John F ^g   Dieudonne, Arry ^h   Abrams, Elaine J ⁱ   Pathak, Indu ^j  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e BELLEVUE HOSPITAL CENTER   (United States)

^f TEXAS CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

^j METROPOLITAN HOSPITAL CENTER   (United States)

^k CHILDREN S HOSPITAL   (United States)

more..

Author keywords

Highly active antiretroviral therapy; Human immunodeficiency virus; Pneumococcal vaccine; Streptococcus pneumoniae

Indexed keywords

ANALGESIC AGENT; ANTIRETROVIRUS AGENT; BACTERIUM ANTIBODY; IMMUNOGLOBULIN ANTIBODY; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; VIRUS RNA;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PAIN; PHARYNGITIS; PREDICTION; PRIORITY JOURNAL; SEROTYPE; SKIN INDURATION; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RNA, VIRAL; STATISTICS; STATISTICS AS TOPIC; STREPTOCOCCUS PNEUMONIAE;

EID: 33749426110     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000237830.33228.c3     Document Type: Article

References (50)

1. Jordano Q, Falco V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis. 2004;38:1623-1628.
2. Lopez-Palomo C, Martin-Zamorano M, Benitez E, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol. 2004;72:517-524.
3. Klugman KP, Madhi SA, Huebner RE, Kohlberger R, Mbelle N, Pierce N. A trial of 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
4. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2003;31:170-176.
5. Arpadi SM, Back S, O'Brien J, et al. Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine. J Pediatr. 1994;125:77-79.
6. King JC Jr, Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1996;15:192-196.
7. Nielsen H, Kvinesdal B, Benfield TL, et al. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis. 1998;30:597-601.
8. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine. 1999;18:524-530.
9. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1999. Washington, DC: American Society for Microbiology; 1999.
10. French N, Nakiyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomized and placebo controlled trial. Lancet. 2000;355:2106-2111.
11. Tangsinmankong N, Kamchaisatian W, Day NK, Sleasman JW, Emmanuel PJ. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann Allergy Asthma Immunol. 2004;92:558-564.
12. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2003;37:438-447.
13. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine. 2004;22:2006-2012.
14. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 1999;18:757-763.
15. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101:604-611.
16. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children: Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
17. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-361.
18. Barnett ED, Pelton SI, Cabral HJ, et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis. 1999;29:191-192.
19. Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to polysaccharide vaccine. Pediatr Infect Dis J. 1998;17:685-691.
20. Vernacchio L, Neufeld EJ, MacDonald K. Combined schedule of 7-valent penumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr. 1998;133:275-278.
21. Eick A, Croll J, Weatherholtz R, Croll L, Santosham M. Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants. Vaccine. 2004;12:1260-1264.
22. King JC Fr, Vink PE, Chang I, et al. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine. 1998;16:361-365.
23. Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type I infection. Pediatrics. 2003;112:66-73.
24. Huebner RE, Mbelle N, Forrest B, Madore DV, Klugman KP. Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine. Vaccine. 2004;22:2696-2700.
25. Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman K. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005;24:410-416.
26. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, et al. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis. 1996;173:83-90.
27. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine. 2000;19:886-894.
28. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine. 2001;20:545-553.
29. Tarrago D, Casal J, Ruiz-Contreras J, et al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol. 2005;12:165-170.
30. Feikin DR, Elie CM, Goetz MB, et al. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. Clin Diagn Lab Immunol. 2004;11:137-141.
31. MacDonald NE, Halperin SA, Law BM, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs. plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA. 1998;280:1685-1689.
32. Weinberg A, Wohl DA, Barrett RJ, van der Horst C. Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2001;184:707-712.
33. Weinberg A, Wiznia AA, LaFleur BJ, et al. Varicella-zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2004;190:267-270.
34. Al-Harthi L, Voris J, Patterson BK, et al. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naïve patients. HIV Med. 2004;5:55-65.
35. Cossarizza A, Poccia F, Agrati C, et al. Highly active antiretroviral therapy restores CD4+ Vbeta T-cell repertoire in patients with primary acute HIV infection but not in treatment-naïve HIV+ patients with severe chronic infection. J Acquir Immune Defic Syndr. 2004;35:213-222.
36. Resino S, Rivero L, Ruiz-Mateos E, et al. Immunity in HIV-1-infected adults with a previous state of moderate-severe immune suppression and more than 500 CD4+ T cell after highly active antiretroviral therapy. J Clin Immunol. 2004;24:379-388.
37. Weinberg A, Pahwa S, Oyomopito R, et al. Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:107-114.
38. Crothers K, Huang L. Recurrence of Pneumocystis carinii pneumonia in an HIV-infected patient: apparent selective immune reconstitution after initiation of antiretroviral therapy. HIV Med. 2003;4:346-349.
39. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccination in human immunodeficiency virus-infected children. Clin Infect Dis. 2001;32:1090-1094.
40. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics. 2003;111:e641-644.
41. Lederman HM, Williams PL, Wu JW, et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis. 2003;188:1794-1803.
42. Kroon FP, Rimmelzwaan GF, Roos MTL, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS. 1998;12:F217-223.
43. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003;17:2015-2023.
44. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Adult and Adolescent Spectrum of HIV Disease Project: pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis. 2001;32:794-800.
45. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305-310.
46. Malaspina A, Moir S, Kottilil S, et al. Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol. 2003;170:5965-5972.
47. McCool TL, Schreiber JR, Greenspan NS. Genetic variation influences the B-cell response to immunization with a pneumococcal polysaccharide conjugate vaccine. Infect Immun. 2003;71:5402-5406.
48. Konradsen HB, Henrichsen J, Wachmann H, Holm N. The influence of genetic factors on the immune response as judged by pneumococcal vaccination of mono- and dizygotic Caucasian twins. Clin Exp Immunol. 1993;92:532-536.
49. Kohler PF, Rivera VJ, Eckert ED, et al. Genetic regulation of immunoglobulin and specific antibody levels in twins reared apart. J Clin Invest. 1985;75:883-888.
50. Musher DM, Groover JE, Watson DA, et al. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J Investig Med. 1997;45:57-68.